BiologicalDrug
Mivocabtagene autoleucel clinical trials
Also written KYV-101.
Keep track of what changes. Save the mivocabtagene autoleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
9 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 5
Kyverna Therapeutics (4) · Stanford University (2) · David Porter (1) · Charite University, Berlin, Germany (1) · David Simon (1)
Studies
Open first, then newest update. How each study uses mivocabtagene autoleucel is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple SclerosisRecruitingPhase 1Stanford UniversityNCT06138132Written as KYV-101 anti-CD19 CAR-T cell therapy
- Study of KYV-101 Anti-CD19 CAR T Therapy in Adult DermatomyositisRecruitingPhase 1Stanford UniversityNCT06298019Written as KYV-101
- Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA VasculitisNot yet recruitingPhase 1/2David SimonNCT06590545Written as KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
- CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101Active, not recruitingPhase 1David PorterNCT06152172Written as KYV-101
- KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisTerminatedPhase 1/2Kyverna TherapeuticsNCT06342960Written as KYV-101 anti-CD19 CAR-T cell therapy
- KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisTerminatedPhase 1/2Kyverna TherapeuticsNCT05938725Written as KYV-101 anti-CD19 CAR-T cell therapy
- KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic SclerosisTerminatedPhase 1/2Kyverna TherapeuticsNCT06400303Written as KYV-101
- Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisActive, not recruitingPhase 1/2Charite University, Berlin, GermanyNCT06475495Written as KYV101
- KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisActive, not recruitingPhase 2Kyverna TherapeuticsNCT06384976Written as KYV-101
Given in every arm · 1 — mivocabtagene autoleucel is usual care beside what is tested
Codes
What other systems call mivocabtagene autoleucel · ClinicalTrials.gg INT017711
- UNII (FDA) QTE27WBS5AMIVOCABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C215283Mivocabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QTE27WBS5A | MIVOCABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C215283 | Mivocabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.